With market turbulence dominating the headlines in 2019 it is easy to forget that there is plenty to be optimistic about on the London stock markets.
Creo Medical (CREO) is perhaps one of AIM’s least glamorous companies. It is focused on the emerging field of surgical endoscopy – a multi-billion-pound market which is expanding due to the advent of colorectal cancer screening around the world. Creo is developing a suite of products based on its transformational CROMA electrosurgery advanced energy platform. Its first – the rather oddly named RS2 Speedboat – enables the removal of cancerous and pre-cancerous growths in the gastro-intestinal tract or large legions in the bowel. Lovely stuff. For the 16,000 British people who are diagnosed with bowel cancer every year this technology is…
Sign up and read the full article
Register to continue reading this article.
Get FREE access now
Already a member? Login